In this study, attempt has been made to develop digital controller using a microcontroller to automate the bottling plant and to make it user-friendly for village entrepreneur of our country to increase the production of bottles filled with edible oils, country liquor alcohol, mustered oils, fruit juice, Jam, and Jelly, etc. In this era of rural industrialization, technological revolution/automation conventional plants with the manual bottle filling system are shrinking day by day due to high cost, low efficiency. As a result, the need for automated machinery is increasing in a very fast manner. To hold out the commitment of timely delivery of product and to meet the demand, hi-tech automated production even in rural areas has become essential. The grid interactive 1kW solar power supply as provided by the rural grid for 24x7days ensures the continuous production of this product. The field of automation has a notable impact in the rural society of our country. The design of the controller for automated bottling plant with limited capacity with 200 bottle capacity per shift in a day using microcontroller ATMEGA32, have been developed. The simulation study of functional and operational test on prototype unit has been performed, and the results have been found an encouraging one. The cost economy of prototype unit has been computed and analyzed, and the impact study has been carried out in rural society.
The onset and spread of the SARS-CoV-2 virus have created an unprecedented universal crisis. Although vaccines have been developed against the parental SARS-CoV-2, outbreaks of the disease still occur through the appearance of different variants, suggesting a continuous need for improved and effective therapeutic strategies. Therefore, we developed a novel nanovesicle presenting Spike protein on the surface of the dendritic cellderived extracellular vesicles (DEVs) for use as a potential vaccine platform against SARS-CoV-2. DEVs express peptide/MHC-I (pMHC-I) complexes, CCR-7, on their surface. The immunogenicity and efficacy of the Spikeactivated DEVs were tested in mice and compared with free Spike protein. A 1/10 Spike equivalent dose of DEVs showed a superior potency in inducing anti-Spike IgG titers in blood of mice when compared to dendritic cells or free Spike protein treatment. Moreover, DEV-induced sera effectively reduced viral infection by 55−60% within 15 days of booster dose administration. Furthermore, a 1/10 Spike equivalent dose of DEV-treated mice was found to be equally effective in inducing CD19 + CD38 + Tcells in the spleen and lymph node; CD8 cells in the bone marrow, spleen, and lymph node; and CD4 + CD25 + T-cells in the spleen and lymph node after 90 days of treatment. Thus, our results support the immunogenic nature of DEVs, demonstrating that a low dose of DEVs induces antibodies to inhibit SARS-CoV-2 infection in vitro, therefore warranting further investigations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.